BCR and chronic myelogenous leukemia, BCR-ABL1 positive: The identification of imatinib as an effective therapy for chronic myeloid leukemia (CML) harboring the BCR-ABL1 fusion marked a turning point in cancer treatment, highlighting the potential of targeting gene fusions.1